جست‌وجوی استاد و پژوهشگر

• Actin Cytoskeleton
• Cell Adhesion
• Intestinal Polyps
• +۶ مورد دیگر

Kaelyn Sumigray is an Assistant Professor in the Department of Genetics at Yale School of Medicine. She holds a PhD in Cell Biology from Duke University (2011) and postdoctoral training at UNC Chapel Hill and Duke University. Her research focuses on intestinal epithelial biology, stem cell dynamics, and morphogenesis, with particular interest in CFTR high-expresser cells and intestinal pathologies like cystic fibrosis and microvillus inclusion disease. She co-directs the Yale Summer Enrichment Research Experience (YSERE) and serves on multiple institutional committees including Yale Genetics Department Mentoring Committee and Yale Cancer Center. Education B.S., Biology, Union College (2006) Ph.D., Cell Biology, Duke University (2011) Research Interests Dr. Sumigray investigates intestinal epithelial morphogenesis, stem cell niches, and disease mechanisms in cystic fibrosis and microvillus inclusion disease. Her lab uses organoid models and coculture systems to study epithelial-fibroblast interactions, CFTR function, and pH-sensing neuropod cells. Key themes include intestinal regeneration, cell polarity, and the role of serotonin in epithelial proliferation. Publications Overview Recent work highlights sex-specific effects of asparagine on colorectal tumors, lysosomal protein degradation mechanisms, and CFTR high-expresser cells' role in cystic fibrosis. Her articles span molecular biology, cell biology, and translational gastroenterology, emphasizing interdisciplinary approaches. Awards Chen Innovation Award (2022) Dermatology Foundation Basic Research Award (2014) Grants & Advising Active in peer review for journals including Nature Cell Biology and the Journal of Clinical Investigation. Mentors students through Yale's Genetics Department and BBS program. Leads initiatives to enhance diversity in STEM through YSERE and institutional committees. Labs & Teams Leads the Sumigray Lab focused on intestinal epithelial biology. Collaborates with the Janeway Society and Yale Stem Cell Center on interdisciplinary projects.

• Cardiovascular Diseases
• Molecular Biology
• Physiology
• +۶ مورد دیگر

Dr. Eddy Kizana is a Senior Lecturer in Medicine at the University of Sydney's Westmead Clinical School, specializing in Cardiology and Cardiovascular Research. His affiliations include the Westmead Clinical School and collaborations across multiple disciplines within the University. His research focuses on cardiovascular diseases, gene therapy applications for arrhythmias, and molecular mechanisms underlying cardiac dysfunction. Key themes include Obesity, Diabetes, and Healthy Ageing, with a strong emphasis on translational research. Research Interests: Cardiac arrhythmia mechanisms and treatments Gene therapy for cardiac repair Cardiac fibrosis and remodelling Therapeutic delivery systems for heart disease His recent publications highlight advancements in gene vector engineering, arrhythmia substrate characterization, and translational models for cardiac regeneration. Current research students are investigating novel gene therapies for cardiac arrhythmias and catheter ablation strategies. Grants and collaborations include projects on atrial cardiomyopathy phenotyping ( NSW Health ), bioengineered antiarrhythmic models ( MRFF ), and cardiac gene therapy vectors ( NHMRC ). His work bridges basic science with clinical applications, addressing gaps in cardiac disease management.

May Sin Keمشاهده پروفایل

پژوهشگر ارشد

• Immunotherapy
• Cancer Biology
• Immunogenetics
• +۳ مورد دیگر

Dr. May Sin Ke is a Junior Research Fellow and Postdoctoral Researcher in the Department of Oncology at the University of Oxford's Old Road Campus. Her research focuses on immunotherapy in cancer, particularly leveraging bispecific monoclonal antibodies for colorectal cancer and adenocarcinomas. She specializes in developing biological assays to model cancer biology and identify therapeutic targets. Her doctoral work at Oxford explored tumour heterogeneity in triple-negative breast cancer under hypoxic conditions using single-cell sequencing. During her BSc at the University of Tsukuba, Japan, she developed 3D spheroid models of dermal papilla cells for hair growth screening. Key research interests include tumour heterogeneity, hypoxia-driven cancer mechanisms, and translational applications of 3D cell culture models. Her recent publications emphasize single-cell technologies and their challenges in understanding cellular diversity in oncology. No scientific awards are listed in the provided text. Her work contributes to therapeutic target discovery through advanced cellular and molecular approaches.

• Cancer Research
• Pharmacology
• Medicinal Chemistry
• +۳ مورد دیگر

Dr. Rebecca Roubin is a Lecturer in the Department of Pharmaceutical and Medicinal Chemistry at the University of Sydney's Faculty of Pharmacy. She holds a BSc (Hons) from UNSW and a PhD. Her research focuses on molecular mechanisms of the tumor microenvironment, particularly in blood cancers like Multiple Myeloma, alongside exploring synergistic nuclear receptor agonists and traditional Chinese medicine (TCM) applications. Collaborations include work with Hong Kong Polytechnic University on PPARγ pathways and immunomodulatory glycoproteins. Her research themes include Cancer, Cardiovascular/ Diabetes, and Health Services. She has published widely on topics ranging from PPAR agonist design to ethnobotanical drug discovery. Key grants include projects on PPARγ agonists (2006) and glycoproteomic diagnostics (2003). She also contributes to pharmacy education and anti-doping practices in athlete care. Education: BSc (Hons) UNSW, PhD International Collaborations: Hong Kong Polytechnic University, Shanxi University (China) Grants: 4 major grants including PPARγ therapy and cartilage gene therapy Labs/Teams: Cancer Immunotherapy Group, TCM Anticancer Research Unit Her work bridges basic science and translational medicine, emphasizing drug development for hard-to-treat cancers and leveraging traditional medicinal knowledge.

• Medicinal Chemistry
• Bio-Inorganic Chemistry
• Cancer Drug Discovery
• +۷ مورد دیگر

Dr. Srinivasa Reddy Telukutla is a Research Fellow at the Department of Research & Innovation Capability, RMIT University. His work focuses on developing novel medicinal and bio-inorganic chemistry approaches for cancer drug discovery, particularly targeting ovarian, melanoma, prostate, and skin cancers. He specializes in synthesizing bioactive gold, platinum, and ruthenium-based metal complexes as chemo-therapeutics and exploring nanotechnology-driven drug delivery systems, such as dendrimers, cubosomes, and MOFs, to enhance therapeutic efficacy and reduce off-target effects. His research also investigates cannabinoids' anti-cancer properties and their delivery mechanisms, including transdermal systems and nanoformulations. Dr. Telukutla has supervised 2 completed PhD students and currently oversees 3 ongoing supervisions. His projects include gold-based drugs for ovarian cancer, hyaluronic acid-based nanohydrogels for CBD delivery in melanoma, and CRISPR/Cas9 gene editing using metal-organic frameworks. He collaborates widely, as evidenced by his multi-authored publications and involvement in interdisciplinary teams. His research interests span medicinal chemistry, oncology, nanotechnology, and pharmacology, with a strong emphasis on translational drug delivery science and mechanism-based drug design. Key contributions include advancing gold complex therapies through ROS-dependent mechanisms and exploring synergistic cannabinoid combinations with existing cancer treatments.

Tien Huynhمشاهده پروفایل

دانشیار

• Environmental Sustainability
• Biomaterials
• Plant Biology
• +۸ مورد دیگر

Dr. Tien Huynh is an Associate Professor in the School of Science at RMIT University, specializing in environmental sustainability, biotechnology, and mycology. Her research bridges ecological conservation, medicinal plant applications, and advanced materials engineering, with a focus on sustainable solutions for environmental and health challenges. She holds a PhD from the University of Melbourne and has conducted postdoctoral work in the UK and Italy. Education: PhD in Biological Sciences, University of Melbourne (2004) Postdoctoral Research, University of Cambridge (UK) and University of Florence (Italy) Research Interests: Environmental sustainability and conservation Plant pathology and mycorrhizal symbiosis Medicinal plants for cancer, diabetes, and neurodegenerative diseases Biomaterials and fire-resistant composites from agricultural waste Neuropharmacology and drug discovery Awards & Recognition: Superstars of STEM award (Science and Technology Australia, 2023) Grants & Projects: Bulloak Conservation Project (Wettenhall Environmental Trust, 2018) New Colombo Plan Program (Australian Government, 2017) Biodiversity On Grounds Action Grant (Victorian Government, 2017) Outreach & Industry Collaboration: International study programs in Asia for students Industry partnerships for sustainable material development Community engagement in conservation and education

Jean-François CARRIERمشاهده پروفایل

استاد

• Medical Physics
• Radiation Oncology
• Medical Imaging
• +۴ مورد دیگر

Jean-François Carrier is a Full Professor at the University of Montreal's Faculty of Arts and Sciences, Department of Physics. He leads research in medical physics, focusing on improving radiation oncology treatments and imaging techniques, with clinical applications in radiation therapy and nuclear medicine. His work integrates advanced technologies like Monte Carlo simulations, dual-energy CT, and AI-driven image analysis. Affiliations: Research Center of the University of Montreal Hospital Center (CRCHUM), Centre Hospitalier de l'Université de Montréal (CHUM). Research Interests: Radiation detectors, dosimetry, Monte Carlo simulations, and translational radiation oncology. His group collaborates with clinical personnel in radiation oncology departments to develop practical solutions for treatment planning and imaging. Grants and Projects: Over 20 active and completed projects funded by CRSNG, FRQS, MITACS, and others. Recent grants include advancements in PET imaging, alpha particle therapy, and AI-driven dose calculation algorithms. Teaching: Courses include Radiology and Radiation Protection, Medical Physics Special Topics, and Medical Imaging modalities. Supervises graduate programs in Biophysics and Molecular Physiology, and Physics Doctorate. Labs and Teams: Part of the TransMedTech Montreal initiative and the Imaging and Engineering Axis at CRCHUM, focusing on engineering solutions for healthcare challenges.

Lauren Brownمشاهده پروفایل

استاد پژوهشی

• Medicinal Chemistry
• Infectious Diseases
• Antifungal Therapies
• +۵ مورد دیگر

Lauren Brown is a Research Professor at Boston University, affiliated with the Boston University Center for Molecular Discovery (BU-CMD). Her research focuses on medicinal chemistry targeting infectious diseases, including antifungal therapies for Cryptococcal and Candida infections, antiviral agents against poxviruses, and antiparasitic treatments for leishmaniasis. She also leads collaborative efforts within the Chemical Library Consortium (CLC) to explore small molecule libraries for oncology, neuroscience, and metabolic disorder applications. Education: B.A. in Biochemistry (cum laude) from the University of Southern California (2003), Ph.D. in Chemistry and Biochemistry from the University of California, Santa Cruz (2009). She serves as Associate Director of the NIH-funded BU-CMD, which specializes in chemical library synthesis and biomedical research. Research interests include computational modeling, organic synthesis of bioactive molecules, and translational drug discovery. Key projects involve eIF4A inhibition for cancer and fungal pathogen treatments, as well as Hsp90-selective antifungal development. Alumni of her lab include industry leaders at AstraZeneca, Amgen, and Foghorn Therapeutics. Her work spans diverse therapeutic areas, with recent studies on rocaglate derivatives for SARS-CoV-2, glioblastoma stem cells, and neuroblastoma. BU-CMD collaborations drive innovation in small molecule libraries and drug repurposing strategies.

Scott Manalisمشاهده پروفایل

استاد

• Cancer Biology
• Precision Medicine
• Single-Cell Analysis
• +۵ مورد دیگر

Scott Manalis is the David H. Koch (1962) Professor of Engineering at MIT, holding dual appointments in Biological Engineering and Mechanical Engineering. He serves as Associate Department Head of Biological Engineering and is a member of the MIT Center for Precision Cancer Medicine, Ludwig Center at MIT, and the Broad Institute. His lab develops precision measurement technologies for single-cell analysis, focusing on biophysical properties relevant to cancer and immune cell dynamics. Key innovations include the suspended microchannel resonator for cell mass measurement and high-throughput density profiling. Education: B.S. in Physics from UC Santa Barbara; Ph.D. in Applied Physics from Stanford University. He founded Travera and Affinity Biosensors to commercialize his lab's technologies. His research spans precision medicine, microfluidic device engineering, and environmental microbiology. Notable achievements include predicting cancer drug responses through single-cell mass dynamics and revealing biophysical changes during cell division. Research emphasizes functional assays for personalized medicine, with a focus on metastasis, immune cell profiling, and minimal residual disease. Over 100 publications highlight his interdisciplinary approach, integrating engineering, biology, and clinical science. Administrative support is provided by Mariann Murray (mariann@mit.edu). His lab’s work has been featured in MIT News and Nature Biomedical Engineering. Students and alumni include pioneers in biotechnology, academia, and industry, such as Rob Kimmerling (Co-founder, Travera) and Marcio von Muhlen (Co-founder, Turboprop). Current lab members include postdocs and graduate students working on projects ranging from CAR-T cell optimization to AAV gene therapy characterization. Collaborations with Dana-Farber Cancer Institute and Broad Institute underscore translational impact.

Christopher Burgeمشاهده پروفایل

استاد

• RNA splicing
• Gene regulation
• Molecular biology
• +۳ مورد دیگر

Christopher Burge is the Uncas (1923) and Helen Whitaker Professor at the Massachusetts Institute of Technology (MIT), affiliated with the Koch Institute for Integrative Cancer Research (KIICR) and the Broad Institute. He holds roles as CSB Program Director and Associate Member of the Broad Institute. His research integrates experimental and computational approaches to study RNA splicing regulatory codes, RNA-binding proteins, and post-transcriptional gene regulation in biological systems. He earned a BS (1990) and PhD (1997) in Biological Sciences from Stanford University. Research interests focus on understanding how RNA splicing is regulated across cell types, including the role of RNA-binding proteins and 3'UTR functions in mRNA localization and microRNA regulation. Key contributions include mapping RNA-binding protein affinity spectra and linking them to in vivo activity. His work bridges computational modeling with experimental validation, addressing fundamental biological mechanisms. Recent publications highlight advancements in identifying disease-associated genetic variants, RNA-protein interaction dynamics, and species-specific regulatory mechanisms. Notable awards include the Schering-Plough Research Institute Award (2007) and Overton Prize for Computational Biology (2001). His lab's interdisciplinary approach addresses complex questions in gene regulation and molecular biology.

David Waldمشاهده پروفایل

استاد

• Leukemia
• Cancer Drug Development
• Molecular Oncology
• +۱ مورد دیگر

David Wald, MD, PhD, is Professor of Pathology at Case Western Reserve University School of Medicine. He co-leads the Immune Oncology Program at the Case Comprehensive Cancer Center and serves as Associate Director of the Medical Scientist Training Program. His research focuses on developing novel therapeutic strategies for acute myeloid leukemia (AML), with particular emphasis on ATP depletion-mediated differentiation, nucleoside analogues, and kinase targeting. Dr. Wald completed his MD/PhD training at CWRU and clinical pathology residency at University Hospitals Cleveland Medical Center. Research Interests: Cellular cancer therapies, leukemia genomics, and drug development pipelines using in vitro and murine models. Current projects investigate ectopic fat-cardiomyocyte crosstalk and redox regulation in cancer differentiation pathways.

• Stem Cell Biology
• Cell Reprogramming
• Gene Expression Regulation
• +۳ مورد دیگر

Qiao Wu is an Associate Research Scientist in the Department of Cell Biology at Yale School of Medicine, Yale University. Their research focuses on molecular mechanisms underlying cell reprogramming, cancer biology, and epigenetic regulation. Collaborations include work with In-Hyun Park and Shangqin Guo on stem cell reprogramming and gene expression dynamics. Key contributions involve studies on KLF5 acetylation in prostate cancer metastasis, LEM4-driven tamoxifen resistance in breast cancer, and mechanistic insights into serum response factor regulation. Research integrates cell biology, molecular genetics, and systems biology approaches. No formal advisees are listed, but active participation in collaborative projects across cancer and developmental biology is evident. Publications span topics from cancer epigenetics to plant genetics, reflecting interdisciplinary expertise. Recent work (2023) explores morphomechanic regulation of cell identity and gene expression stability. Experimental systems include in vitro cell models, mouse models, and genetic analysis of maize mutants. Research highlights the interplay between epigenetic modifications, signaling pathways, and cell fate decisions in health and disease.

Sakari Kauppinenمشاهده پروفایل

استاد

• MicroRNA Therapeutics
• RNA Biology
• Cancer Biology
• +۳ مورد دیگر

Sakari Kauppinen is a Professor at the Department of Clinical Medicine, Faculty of Medicine, Aalborg University. His research focuses on microRNA biology, therapeutic applications, and their roles in diseases such as cancer, neurodegeneration, and metabolic disorders. He leads projects like the 2024 initiative exploring microRNA-22’s role in Duchenne Muscular Dystrophy. Notable contributions include pioneering microRNA-targeted drugs and advancing antisense oligonucleotide technologies. His work spans from basic RNA mechanisms to clinical translation, with collaborations in drug development and biomarker discovery. Kauppinen’s team is part of the Center for RNA Medicine, emphasizing interdisciplinary research in RNA-based therapies. Education details are not explicitly stated, but his career reflects advanced expertise in molecular biology and pharmacology. Key research interests include RNA interference mechanisms, microRNA regulatory pathways, and their modulation in disease contexts. He has authored over 70 publications, including seminal reviews on microRNA therapeutics and patents for innovative nucleic acid compounds. Media highlights include discussions on RNA medicine’s potential post-Nobel recognition and contributions to grants like the Novo Nordisk Foundation funding. Labs/Teams: Active member of the Center for RNA Medicine at Aalborg University. Collaborative projects involve institutions globally, focusing on translational RNA research.

• Molecular Biology
• Cellular Biology
• Cancer Biology
• +۳ مورد دیگر

Vi Lee is a Post Graduate Associate at the Yale School of Medicine, Yale University. She holds an MS in Personalized Medicine & Applied Engineering (expected 2024) from Yale and a BS in Biomolecular Science from New York University (2022). Her research focuses on lipid droplet biology, oncogenic signaling pathways, metabolic regulation, and cardiovascular mechanisms. Key research interests include understanding lipid droplet functions in metabolic diseases, molecular mechanisms of RAS oncogene activation, and endothelial cell interactions in cardiac tissue. Her work bridges systems biology approaches with translational medicine, particularly in cancer biology and vascular health. Publications highlight contributions to lipid droplet proteomics, oncogene regulation via PPP6C, and endothelial-mediated cardiac fibroblast signaling. Current projects explore metabolic gene regulation through MLX-family transcription factors and lipid transport pathways in endothelial cells. No scientific awards are listed in available records. She has been involved in collaborative studies including genome-wide RNAi screens for HPV entry factors and retromer complex functions. Research has implications for developing therapeutic strategies targeting lipid metabolism and vascular diseases.

• Radiation Biology
• Medical Physics
• Dosimetry
• +۱۲ مورد دیگر

Professor Giuseppe Schettino is a Professor of Medical Physics at the University of Surrey with a joint appointment at the National Physical Laboratory (NPL). He also holds honorary positions as Senior Lecturer at Queen’s University Belfast and University College London. His academic journey began with a degree in Nuclear Physics from the University of Naples (1994) and a PhD from King’s College London (1999), followed by postdoctoral work at the Gray Cancer Institute and Columbia University. He served as a Lecturer at Queen’s University Belfast (2007–2013) before joining NPL as Principal Research Scientist (2013–2018), where he later became Head of Science for Medical Physics. Education: PhD in Physics, King’s College London, UK (1999) Laurea in Nuclear Physics, University of Naples, Italy (1994) His research focuses on radiation biology, advanced radiotherapy, and dosimetry , with emphasis on MRI-guided radiotherapy, proton and ion beam therapy, microdosimetry, and nanoparticle-based radiosensitization. He leads UK efforts in standardizing dosimetry and QA for preclinical radiotherapy, funded by Innovate UK and supported by CTRad and Cancer Research UK. His recent publications (2020–2023) reflect a strong trend in preclinical radiotherapy, 3D tumour models, dosimetry innovation, and biological effects of radiation . Key themes include radiomics, magnetic field interactions, and nanoparticle applications in cancer therapy. Scientific Awards and Recognition: No explicitly listed awards, but leadership in nationally funded programs indicates recognition. He has advised and collaborated with numerous researchers across institutions. Though no formal student list is provided, his senior authorship on multiple studies suggests mentorship roles. He is actively involved in developing anthropomorphic phantoms, end-to-end QA tests, and novel detectors for preclinical research. Labs and Teams: Medical Radiation Group, National Physical Laboratory Collaborations with Queen’s University Belfast, UCL, and international radiobiology consortia Lead of UK standardization initiatives in preclinical dosimetry